Literature DB >> 29626472

Tyrosine kinase activity of EphA2 promotes its S897 phosphorylation and glioblastoma cell proliferation.

Yuho Hamaoka1, Manabu Negishi2, Hironori Katoh3.   

Abstract

EphA2, a member of the Eph family of receptor tyrosine kinases, has been reported to promote tumor malignancy through phosphorylation of serine 897 (S897). Here, we found that overexpression of wild-type EphA2 induced S897 phosphorylation through ERK activation without growth factors or cytokines and promoted glioblastoma cell proliferation. However, overexpression of a kinase-inactive mutant of EphA2 failed to induce ERK activation, S897 phosphorylation, and promotion of glioblastoma cell proliferation. These data suggest that when overexpressed, EphA2 induces ERK activation through its tyrosine kinase activity, leading to S897 phosphorylation and promotion of glioblastoma cell proliferation. Our findings provide a new insight into how EphA2 mediates glioblastoma progression.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell proliferation; ERK; EphA2; Glioblastoma

Mesh:

Substances:

Year:  2018        PMID: 29626472     DOI: 10.1016/j.bbrc.2018.04.020

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Genomic and transcriptomic characterization of the human glioblastoma cell line AHOL1.

Authors:  W A S Ferreira; C K N Amorim; R R Burbano; R A R Villacis; F A Marchi; T S Medina; M M C de Lima; E H C de Oliveira
Journal:  Braz J Med Biol Res       Date:  2021-01-15       Impact factor: 2.590

Review 2.  EphA2 and EGFR: Friends in Life, Partners in Crime. Can EphA2 Be a Predictive Biomarker of Response to Anti-EGFR Agents?

Authors:  Mario Cioce; Vito Michele Fazio
Journal:  Cancers (Basel)       Date:  2021-02-09       Impact factor: 6.639

3.  Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin.

Authors:  Marco Rusnati; Giulia Paiardi; Chiara Tobia; Chiara Urbinati; Alessio Lodola; Pasqualina D'Ursi; Miriam Corrado; Riccardo Castelli; Rebecca C Wade; Massimiliano Tognolini; Paola Chiodelli
Journal:  Cancer Gene Ther       Date:  2021-08-23       Impact factor: 5.854

4.  Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer.

Authors:  Elina A Pietilä; S Pauliina Turunen; Lidia Moyano-Galceran; Sara Corvigno; Elisabet Hjerpe; Daria Bulanova; Ulrika Joneborg; Twana Alkasalias; Yuichiro Miki; Masakazu Yashiro; Anastasiya Chernenko; Joonas Jukonen; Madhurendra Singh; Hanna Dahlstrand; Joseph W Carlson; Kaisa Lehti
Journal:  EMBO Mol Med       Date:  2020-03-02       Impact factor: 12.137

5.  Kinome Array Profiling of Patient-Derived Pancreatic Ductal Adenocarcinoma Identifies Differentially Active Protein Tyrosine Kinases.

Authors:  Justin F Creeden; Khaled Alganem; Ali S Imami; F Charles Brunicardi; Shi-He Liu; Rammohan Shukla; Tushar Tomar; Faris Naji; Robert E McCullumsmith
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

Review 6.  Targeting EphA2 in cancer.

Authors:  Ta Xiao; Yuhang Xiao; Wenxiang Wang; Yan Yan Tang; Zhiqiang Xiao; Min Su
Journal:  J Hematol Oncol       Date:  2020-08-18       Impact factor: 17.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.